Cystic Fibrosis News

Percent-predicted FEV1 and respiratory-related quality of life improved with 28-day triple therapy in individuals with the N1303K cystic fibrosis transmembrane conductance defect, according to data published in Lancet Respiratory Medicine.

Patients with COPD, asthma and cystic fibrosis may soon be able to monitor their diseases by using/breathing through a tool that connects to their smartphone, according to a University of Pittsburgh press release.

BOSTON — Hospitalization for a cardiac cause vs. a noncardiac cause in patients with cystic fibrosis yielded elevated in-hospital mortality, according to a presentation at the CHEST Annual Meeting.

BOSTON — Having vs. not having past cystic fibrosis transmembrane conductance regulator modulator exposure did not change positive outcomes seen with elexacaftor/tezacaftor/ivacaftor, according to data presented at the CHEST Annual Meeting.

Lumacaftor/ivacaftor showed improvements in several measures in children aged 2 to 5 years homozygous for F508del-CFTR over 96 weeks, according to results published in Annals of the American Thoracic Society.

Lung clearance index and MRI scores improved in kids aged 6 to 11 years with cystic fibrosis and at least one F508del allele receiving elexacaftor/tezacaftor/ivacaftor therapy, according to results published in European Respiratory Journal.

Although inhaled antisense oligonucleotide treatment is safe, its efficacy needs to be determined in patients with the cystic fibrosis splicing mutation 3849+10kb C-to-T, according to a press release from the Cystic Fibrosis Foundation.

It is known that persons with cystic fibrosis are more susceptible to infections; however, the impact of elexacaftor/tezacaftor/ivacaftor therapy on this susceptibility has not been well studied yet.

When asked about newborn screening tests, nearly half of surveyed parents with a young child did not know the conditions included on these tests, according to results presented at the Pediatric Academic Societies Meeting.